Prothena Corporation plc
25-28 North Wall Quay
Dublin
1
Tel: 353-1-902-3519
Fax: 353-1-902-3510
Website: http://www.prothena.com
Email: info@prothena.com
168 articles with Prothena Corporation plc
-
BioSpace takes a look at some notable programs that have been shuttered so far this year.
-
One month after Prothena Corporation shuttered its NEOD001 program for AL amyloidosis following a Phase IIb failure, the company initiated a reorganization that includes a workforce reduction of 57 percent.
-
Celgene is eying the first quarter of 2019 to submit a second New Drug Application (NDA) for multiple sclerosis treatment ozanimod.
-
Prothena Shareholder Alert - PRTA Stock Drops Almost 70% - Kehoe Law Firm, P.C. Investigating
4/24/2018
Kehoe Law Firm, P.C. is conducting a securities investigation on behalf of investors of Prothena Corporation plc (NASDAQ: PRTA) to determine whether Prothena Corporation and certain of its officers or directors engaged in securities fraud or other unlawful business practices.
-
Prothena Corporation announced it had shuttered its NEOD001 program for AL amyloidosis after the failure of its Phase IIb PRONTO study and Phase III VITAL study. Shares dropped 60 percent in premarket trading at the news.
-
Scott Smith, Celgene’s chief operating officer, abruptly resigned Monday. His decision to leave appears to be prompted by a restructuring of the company’s executive team.
-
Prothena Therapeutics has forged a collaboration with Celgene worth a potential $2B to develop new therapies for a broad range of neurodegenerative diseases.
-
After yesterday's big plunge in the stock market, and today with the Dow Jones Industrial Average dropping more than 500 points after opening, but mostly recovering, volatility appears to be the key word to describe the stock market.
-
Prothena Announces Departure of CMO
2/5/2018
The Company is commencing a search for a replacement.
-
Prothena to Report Fourth Quarter and Full Year 2017 Financial Results and Host Webcast Conference Call on February 14
2/2/2018
The announcement will be followed by a live audio conference call at 4:30 PM ET.
-
Prothena Highlights Breadth of Novel Pipeline at R&D Day
11/16/2017
Prothena management will discuss progress on Prothena’s clinical and discovery programs.
-
Prothena Reports Third Quarter 2017 Financial Results and Provides R&D Update
11/8/2017
Prothena reported a net loss of $52.4 million and $105.5 million for the third quarter and first nine months of 2017.
-
Kerrisdale believes that Prothena's lead drug NEOD001 will fail in its current Phase 2b and Phase 3 trials.
-
Prothena to Report Third Quarter 2017 Financial Results on November 7
11/1/2017
Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on November 7.
-
Prothena Ends An Early Stage Psoriasis Drug After Data Failed To Wow Its Researchers
9/29/2017
-
Prothena Presents New Research Supporting Clinical Relevance Of Cardiac Biomarker NT-Probnp In AL Amyloidosis
9/19/2017
-
Prothena Presents New Research Supporting Clinical Relevance Of Cardiac Biomarker NT-proBNP In AL Amyloidosis
9/18/2017
-
Prothena Reports Second Quarter 2017 Financial Results And Provides R&D Update
8/9/2017
-
Prothena To Report Second Quarter 2017 Financial Results On August 8
8/2/2017
-
Prothena Announces Initiation Of Phase II PASADENA Study Of PRX002/RG7935 In Patients With Early Parkinson’s Disease
7/6/2017